

News Releases

All Years

Search

Go

[Advanced Search](#)

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

SEP 4, 2019

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 30, 2019

Inhibrx Announces Option Agreement for Development and Commercialization of INBRX-101 (AAT-Fc) Outside of the United States and Canada with Chiesi Group

MAY 21, 2019

Inhibrx Announces \$40M Investment from Viking Global Investors

FEB 19, 2019

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-105, a Novel Multispecific PD-L1 and 4-1BB Antibody

JAN 7, 2019

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

DEC 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

OCT 31, 2017

Inhibrx Wins CARB-X Award Of Up To \$6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections

SEP 15, 2015

Inhibrx and The Alpha-1 Project Collaborate to Develop a Recombinant Alpha-1 Antitrypsin with Improved Properties

JUN 27, 2012

Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program

Show per page

« [1](#) [2](#) »



<https://inhibrx.investorroom.com/news-releases?l=50&o=50>